In June 2014 Celsion Corporation (Celsion) (NASDAQ: CLSN) - an oncology drug development company - acquired EGEN, Inc. Expression Genetics, Inc. (EGEN), had been privately held biopharmaceutical company specializing in nucleic acid (DNA and RNAi) delivery and therapeutics aimed at specific disease targets. The Company had been focused on developing therapeutics for the treatment of human diseases including cancer and cardiovascular disease. EGEN has research pipeline products aimed at treatment of various cancers and cardiovascular disease involving siRNA, shRNA, tumor antigens, and angiogenic genes. EGEN has collaborations with outside investigators, biotech organizations, and universities on various projects in these areas.